Activation of AMP-activated Protein Kinase in the Liver: a New Strategy for the Management of Metabolic Hepatic Disorders

Overview

Journal J Physiol

Specialty Physiology

Date 2006 Apr 29

PMID 16644802

Citations 203

Authors

Benoit Viollet

Marc Foretz

Bruno Guigas

Sandrine Horman

Renaud Dentin

Luc Bertrand

Louis Hue

Fabrizio Andreelli

Affiliations

Soon will be listed here.

Abstract

It is now becoming evident that the liver has an important role in the control of whole body metabolism of energy nutrients. In this review, we focus on recent findings showing that AMP-activated protein kinase (AMPK) plays a major role in the control of hepatic metabolism. AMPK integrates nutritional and hormonal signals to promote energy balance by switching on catabolic pathways and switching off ATP-consuming pathways, both by short-term effects on phosphorylation of regulatory proteins and by long-term effects on gene expression. Activation of AMPK in the liver leads to the stimulation of fatty acid oxidation and inhibition of lipogenesis, glucose production and protein synthesis. Medical interest in the AMPK system has recently increased with the demonstration that AMPK could mediate some of the effects of the fat cell-derived adiponectin and the antidiabetic drugs metformin and thiazolidinediones. These findings reinforce the idea that pharmacological activation of AMPK may provide, through signalling and metabolic and gene expression effects, a new strategy for the management of metabolic hepatic disorders linked to type 2 diabetes and obesity.

Citing Articles

Bioactive small compounds effectively inhibit ChREBP overexpression to treat NAFLD and T2DM: A computational drug development approach.

Devnath H, Medha M, Islam M, Biswas P, Oisay D, Hossain A Heliyon. 2025; 11(4):e42477.

PMID: 40034298 PMC: 11872590. DOI: 10.1016/j.heliyon.2025.e42477.

Nidogen 2 Overexpression Promotes Hepatosteatosis and Atherosclerosis.

Kathuria I, Prasad A, Sharma B, Aithabathula R, Ofosu-Boateng M, Gyamfi M Int J Mol Sci. 2024; 25(23).

PMID: 39684493 PMC: 11641205. DOI: 10.3390/ijms252312782.

Loss of protects against MASLD alone or with alcohol intake by preserving lipid homeostasis.

Lamas-Paz A, Hionides-Gutierrez A, Guo F, Jorquera G, Moran-Blanco L, Benede-Ubieto R JHEP Rep. 2024; 7(1):101230.

PMID: 39659733 PMC: 11629569. DOI: 10.1016/j.jhepr.2024.101230.

Fine-tuning AMPK in physiology and disease using point-mutant mouse models.

Ashraf N, Van Nostrand J Dis Model Mech. 2024; 17(8).

PMID: 39136185 PMC: 11340815. DOI: 10.1242/dmm.050798.

Efficacy and Safety of Bempedoic Acid in Patients With Hyperlipidemia and Non-alcoholic Fatty Liver Disease.

Nisar S, Sohail S, Fatima S, Akhtar M, Ahmad M, Hanif M J Community Hosp Intern Med Perspect. 2024; 14(2):40-48.

PMID: 38966508 PMC: 11221442. DOI: 10.55729/2000-9666.1313.

References

Dentin R, Benhamed F, Pegorier J, Foufelle F, Viollet B, Vaulont S . Polyunsaturated fatty acids suppress glycolytic and lipogenic genes through the inhibition of ChREBP nuclear protein translocation. J Clin Invest. 2005; 115(10):2843-54. PMC: 1224299. DOI: 10.1172/JCI25256. View

Matzuk M, WAKIL S . Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science. 2001; 291(5513):2613-6. DOI: 10.1126/science.1056843. View

Krause U, Bertrand L, Maisin L, Rosa M, Hue L . Signalling pathways and combinatory effects of insulin and amino acids in isolated rat hepatocytes. Eur J Biochem. 2002; 269(15):3742-50. DOI: 10.1046/j.1432-1033.2002.03069.x. View

Ferre P, Azzout-Marniche D, Foufelle F . AMP-activated protein kinase and hepatic genes involved in glucose metabolism. Biochem Soc Trans. 2003; 31(Pt 1):220-3. DOI: 10.1042/bst0310220. View

Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies L, Pratipanawatr W, Glass L . Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes. 2003; 52(6):1364-70. DOI: 10.2337/diabetes.52.6.1364. View

Salt I, Celler J, Hawley S, Prescott A, Woods A, Carling D . AMP-activated protein kinase: greater AMP dependence, and preferential nuclear localization, of complexes containing the alpha2 isoform. Biochem J. 1998; 334 ( Pt 1):177-87. PMC: 1219677. DOI: 10.1042/bj3340177. View

Cheng S, Fryer L, Carling D, Shepherd P . Thr2446 is a novel mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status. J Biol Chem. 2004; 279(16):15719-22. DOI: 10.1074/jbc.C300534200. View

Cheung P, Salt I, DAVIES S, Hardie D, Carling D . Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. Biochem J. 2000; 346 Pt 3:659-69. PMC: 1220898. View

Nawrocki A, Rajala M, Tomas E, Pajvani U, Saha A, Trumbauer M . Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem. 2005; 281(5):2654-60. DOI: 10.1074/jbc.M505311200. View

10.

Koo S, Flechner L, Qi L, Zhang X, Screaton R, Jeffries S . The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature. 2005; 437(7062):1109-11. DOI: 10.1038/nature03967. View

11.

Inoki K, Zhu T, Guan K . TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003; 115(5):577-90. DOI: 10.1016/s0092-8674(03)00929-2. View

12.

Leclerc I, Lenzner C, Gourdon L, Vaulont S, Kahn A, Viollet B . Hepatocyte nuclear factor-4alpha involved in type 1 maturity-onset diabetes of the young is a novel target of AMP-activated protein kinase. Diabetes. 2001; 50(7):1515-21. DOI: 10.2337/diabetes.50.7.1515. View

13.

Luo Z, Saha A, Xiang X, Ruderman N . AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci. 2005; 26(2):69-76. DOI: 10.1016/j.tips.2004.12.011. View

14.

Andreelli F, Foretz M, Knauf C, Cani P, Perrin C, Iglesias M . Liver adenosine monophosphate-activated kinase-alpha2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin. Endocrinology. 2006; 147(5):2432-41. DOI: 10.1210/en.2005-0898. View

15.

Screaton R, Conkright M, Katoh Y, Best J, Canettieri G, Jeffries S . The CREB coactivator TORC2 functions as a calcium- and cAMP-sensitive coincidence detector. Cell. 2004; 119(1):61-74. DOI: 10.1016/j.cell.2004.09.015. View

16.

Winder W, Wilson H, Hardie D, Rasmussen B, Hutber C, Call G . Phosphorylation of rat muscle acetyl-CoA carboxylase by AMP-activated protein kinase and protein kinase A. J Appl Physiol (1985). 1997; 82(1):219-25. DOI: 10.1152/jappl.1997.82.1.219. View

17.

Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J . Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001; 108(8):1167-74. PMC: 209533. DOI: 10.1172/JCI13505. View

18.

Kodama S, Koike C, Negishi M, Yamamoto Y . Nuclear receptors CAR and PXR cross talk with FOXO1 to regulate genes that encode drug-metabolizing and gluconeogenic enzymes. Mol Cell Biol. 2004; 24(18):7931-40. PMC: 515037. DOI: 10.1128/MCB.24.18.7931-7940.2004. View

19.

Horman S, Browne G, Krause U, Patel J, Vertommen D, Bertrand L . Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr Biol. 2002; 12(16):1419-23. DOI: 10.1016/s0960-9822(02)01077-1. View

20.

Peralta C, Bartrons R, Riera L, Manzano A, Xaus C, Gelpi E . Hepatic preconditioning preserves energy metabolism during sustained ischemia. Am J Physiol Gastrointest Liver Physiol. 2000; 279(1):G163-71. DOI: 10.1152/ajpgi.2000.279.1.G163. View